Time burden, time spent at home, and persistence with azacitidine or decitabine plus venetoclax in newly diagnosed acute myeloid leukemia in the United States

Pooled Phase 1/2 safety and efficacy analysis of oral azacitidine-cedazuridine versus subcutaneous azacitidine in patients with myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasms